Thus, Al-Mulhim et al. have demonstrated that the subcutaneously inoculation in rats of MCF-7 breast adenocarcinoma cells, engineered by CRISPR/Cas9 to either activate CDH1 or knock out CDK1, resulted in minimal tumor cells infiltration and invasion, indicating that dual targeting could be a better mechanism to inhibit metastasis of breast cancer in vivo [115]. This evidence concerns the gene CDH1 and neoplasm.